MLSS logo

Milestone Scientific Inc. Stock Price

NYSEAM:MLSS Community·US$40.7m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

MLSS Share Price Performance

US$0.52
-0.33 (-39.05%)
74.1% undervalued intrinsic discount
US$2.00
Fair Value
US$0.52
-0.33 (-39.05%)
74.1% undervalued intrinsic discount
US$2.00
Fair Value
Price US$0.52
AnalystHighTarget US$2.00
AnalystConsensusTarget US$1.63
AnalystLowTarget US$1.25

MLSS Community Narratives

AnalystHighTarget·
Fair Value US$2 74.1% undervalued intrinsic discount

Aging Populations And Emerging Markets Will Drive Minimally Invasive Procedures

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value US$1.63 68.1% undervalued intrinsic discount

Global Expansion And Minimally Invasive Care Will Shape Future Progress

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystLowTarget·
Fair Value US$1.25 58.5% undervalued intrinsic discount

Healthcare Cost Pressures Will Limit Adoption Yet Progress Will Emerge

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent MLSS News & Updates

User avatar

CompuFlo Epidural System Will Unlock New Global Opportunities

Strategic partnerships and regulatory approvals are expanding market access for the CompuFlo Epidural System, potentially driving significant revenue growth.

Milestone Scientific Inc. Key Details

US$9.1m

Revenue

US$2.5m

Cost of Revenue

US$6.6m

Gross Profit

US$13.6m

Other Expenses

-US$7.0m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-0.089
Gross Margin
72.80%
Net Profit Margin
-76.78%
Debt/Equity Ratio
24.0%

Milestone Scientific Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Slight risk with mediocre balance sheet.

4 Risks
1 Reward

About MLSS

Founded
1989
Employees
17
CEO
Eric Hines
WebsiteView website
www.milestonescientific.com

Milestone Scientific Inc., a biomedical technology company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical and dental use in the United States, China, and internationally. It operates through Dental and Medical segments. The company provides the Wand, a single use disposable handpiece device for dental procedures that require local anesthetic under the CompuDent and STA Single Tooth Anesthesia System names. It also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, the company provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications. Further, it offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Roseland, New Jersey.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -2.7%
  • 3 Months: 5.1%
  • 1 Year: 13.4%
  • Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.7%, driven by a loss of 2.5% in the Information Technology sector. In the last year, the market is actually up 13%. Earnings are forecast to grow by 15% annually. Market details ›